[Abstract Only] Survival with Olaparib in metastatic castration-resistant prostate cancer
20 Sep, 2020 | 21:13h | UTC
Commentary on Twitter
The PROfound trial showed that olaparib prolonged imaging-based progression-free survival among patients whose tumors contained defects in the BRCA1, BRCA2, or ATM. With longer follow-up, the trial now shows that olaparib prolonged overall survival in these patients. #ESMO20
— NEJM (@NEJM) September 20, 2020